Oral News and Research

RSS

LUHS nurses earn professional certifications

Several Loyola University Health System (LUHS) nurses have earned professional certifications in their clinical areas of expertise. This indicates that LUHS nurses meet strong professional development standards and competencies.

11 Feb 2010

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

QRxPharma Limited announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.

11 Feb 2010

Top ten myths about sex

Boston Medical Group, a national physician network specializing in the treatment of erectile dysfunction and premature ejaculation, today released ten of the top myths surrounding sex. From which gender spends the most time fantasizing to whether size really matters, the list covers some of the common misconceptions about time spent between the sheets.

10 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

People living with IBD are at high risk of blood clots

People living with Inflammatory Bowel Disease (IBD) are known to be at high risk of blood clots when admitted to hospital during a flare-up of their disease but now new research by scientists at The University of Nottingham has shown that those who are not admitted to hospital during flare-ups are also at risk.

10 Feb 2010

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated with concomitant use of clopidogrel and PPIs.

10 Feb 2010

Pivotal Research to study investigational drug for menstrual cramps

A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

10 Feb 2010

Rating of risk factors associated with cardiovascular disease: Low IQ follows cigarette smoking

While lower intelligence scores - as reflected by low results on written or oral tests of IQ - have been associated with a raised risk of cardiovascular disease, no study has so far compared the relative strength of this association with other established risk factors such as obesity, smoking and high blood pressure. Now, a large study funded by Britain's Medical Research Council, which set out to gauge the relative importance of IQ alongside other risk factors, has found that lower intelligence scores were associated with higher rates of cardiovascular disease and total mortality at a greater level of magnitude than found with any other risk factor except smoking.

10 Feb 2010

USPTO awards Transcept Pharmaceuticals patent covering Intermezzo's composition and usage method

Transcept Pharmaceuticals, Inc. today announced that the first patent covering the composition and method of use of Intermezzo® (zolpidem tartrate sublingual tablet), the lead Transcept product candidate, has been issued by the United States Patent and Trademark Office.

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

2010 HSR Impact Award recognizes research that improves patient safety and surgical outcomes

AcademyHealth today recognized research that improves patient safety and surgical outcomes with the 2010 Health Services Research (HSR) Impact Award. The WHO Surgical Safety Checklist was created as a tool to ensure adherence to basic safety standards of care.

9 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Leading researchers discuss latest breakthroughs and best forms of cancer prevention

Eating a balanced diet and preparing your food in the correct way may be your best defense against developing cancer, according to top cancer researchers

9 Feb 2010

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

Resverlogix Corp. announced today the completion of patient enrollment in the Phase 2 clinical study of its lead drug RVX-208. "The completion of enrollment for our Phase 2 ASSERT trial, a full 5 months ahead of our original schedule, is a very exciting achievement for our staff and our collaborators at the Cleveland Clinic.

9 Feb 2010

New nursing education modules now available from March of Dimes

For nurses seeking up-to-date and cost-effective continuing education on the care of mothers and babies, the March of Dimes is now offering three new publications (modules).

9 Feb 2010

NexMed raises $2.3M through private placement

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology , announced today that it has raised $2.3 million in a private placement of promissory notes from two accredited U.S. investors. The promissory notes, due on or before August 4, 2010, are repayable at NexMed’s option in either cash or shares of unregistered common stock at prices ranging from $0.36 to $0.40 per share.

9 Feb 2010

Journal highlights toxic nature of herbal medicines

A University of Adelaide forensic pathologist has sounded a worldwide warning of the potential lethal dangers of herbal medicines if taken in large quantities, injected, or combined with prescription drugs.

9 Feb 2010

Genta commences Phase 2 trial of tesetaxel on first subject

Genta Incorporated announced that the Company has initiated treatment of the first subject in a new Phase 2 trial of tesetaxel in advanced melanoma. Tesetaxel is the Company’s newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development. The new trial builds on more than ten years of Genta’s experience in melanoma clinical research.

9 Feb 2010

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that they have amended the marketing and distribution agreement for oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS). Under the new agreement, Teva extended its marketing and distribution rights to include the Nordic and Baltic regions, previously held by Active Biotech. Active Biotech will receive a higher royalty rate for sales in these territories compared to the royalty rate set under the original licensing agreement signed in 2004 for sales in the rest of the world.

9 Feb 2010

SCL offers nonprofit orthodontic program for children and adolescents

There are two months until the April 15 tax deadline, and if your family has experienced a decrease in income due to the economic downturn, you may now qualify for a low-cost nonprofit orthodontic program. Smiles Change Lives (SCL) is looking for kids from low-income families who need braces.

8 Feb 2010

Oral News and Research

LUHS nurses earn professional certifications

QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR

Top ten myths about sex

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

People living with IBD are at high risk of blood clots

Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial

Pivotal Research to study investigational drug for menstrual cramps

Rating of risk factors associated with cardiovascular disease: Low IQ follows cigarette smoking

USPTO awards Transcept Pharmaceuticals patent covering Intermezzo's composition and usage method

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

2010 HSR Impact Award recognizes research that improves patient safety and surgical outcomes

Biogen Idec reports 2009 fourth quarter and full year earnings

Leading researchers discuss latest breakthroughs and best forms of cancer prevention

Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule

New nursing education modules now available from March of Dimes

NexMed raises $2.3M through private placement

Journal highlights toxic nature of herbal medicines

Genta commences Phase 2 trial of tesetaxel on first subject

Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions

SCL offers nonprofit orthodontic program for children and adolescents

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News